The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Amgen’s Tepezza ...

iOnctura has begun a randomized phase 1/2 study investigating its lead asset, roginolisib, in combination with dostarlimab, ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Amgen’s Tepezza (teprotumumab) as the first licensed treatment for adults with ...

UCB has announced that its developmental treatment DoxTM, a combination of doxecitine and doxribtimine, has been granted ...

The Americas Awards are excited to introduce a new category, Clinical Trial Administrator. This category is designed to ...

Janssen-Cilag International NV, a Johnson & Johnson company, has submitted an application to the European Medicines Agency ...